ULK1/2 Inhibitors that Degrade ATG13 Effectively Target KRAS-Mutant Cancers
Patrick M. Hagan, Huiyu Ren, Sonja N. Brun, Fabiana Izidro Layng, Dhanya R. Panickar, Lester J. Lambert, Maria Celeridad, Ranajit Das, Ling Li, Yijuan Zhang, Allison S. Limpert, Douglas J. Sheffler, Cosimo Commisso, Reuben J. Shaw, Nicholas D. P. Cosford
The paper identifies SBP-1750, a ULK inhibitor that degrades ATG13 and kills KRAS-mutant cancer cells, showing efficacy in vivo and immune enhancement.
bioRxiv · Oct 14, 2025 · PreprintCancer Biology